Updated on 8 June 2012
Utilizing its technological advantages accumulated in the field of traditional fermentation, NCPC has initiated modern biotech research and has set up a biotech drugs development system. NCPC has launched G-CSF, GM-CSF, EPO and genetically engineered hepatitis B vaccines into the market.
Capturing the international market, NCPC's lincomycin hydrochloride, amphotericin B, and oxytetracycline have been approved by FDA. Escalating the quality of products to international standards, NCPC has built its manufacturing capacity strictly in compliance with international standards. NCPC has established its own internal quality control standards, which are much stricter than mandatory standards.
Gradually moving ahead, NCPC is transforming from generics to innovative drug development.